Financials · mywealthgrid

Loading page…

Annual Quarterly

Consolidated Standalone

Consolidated figures · ₹ crore

₹ Cr	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	2,184	2,217	2,133	2,079	2,319
COGS	1,571	1,547	1,397	1,392	1,487
Gross profit	614	670	736	687	832
	355	444	505	485	563
	258	226	231	202	269
OPM %	11.8%	10.2%	10.8%	9.7%	11.6%
Depreciation	43	46	63	72	80
Interest	8	16	16	15	15
	18	26	30	22	10
Profit before tax	225	189	182	138	184
Tax	57	50	47	37	47
Tax %	25.4%	26.2%	26%	26.7%	25.3%
	168	139	134	101	138
PAT margin %	7.7%	6.3%	6.3%	4.9%	5.9%
EPS (₹)	28.6	23.7	22.9	3.4	4.7
EPS adjusted (₹)	5.7	4.7	4.6	3.4	4.7
	14%	16.9%	21.8%	116.3%	—
Annual report	Annual report for Mar 2022	Annual report for Mar 2023	Annual report for Mar 2024	Annual report for Mar 2025	Annual report for Mar 2026

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity capital	59	59	59	59	59	59
Reserves	—	1,334	1,449	1,553	1,629	1,740
	—	43	80	33	117	132
	—	527	435	600	577	656
Total equity & liabilities	—	1,962	2,022	2,244	2,382	2,587
	512	561	752	933	1,171	1,178
CWIP	—	102	81	100	21	94
Investments	—	2	20	20	21	21
	—	1,297	1,169	1,191	1,170	1,294
Total assets	—	1,962	2,022	2,244	2,382	2,587

₹ Cr	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	93	122	290	179	214
	-120	-120	-191	-154	-198
	-2	-4	-93	46	-29
Net cash flow	-29	-2	6	70	-13
Free cash flow	-60	-90	16	-35	41
CFO / Operating profit %	36%	54.2%	125.8%	88.3%	79.7%

Segment results

As reported in NSE results XBRL. Segment result is before tax and finance costs. ROCE uses that annual result divided by segment assets less liabilities.

Source XBRL ↗

Latest reported period · 31 Mar 2026 · ₹ crore

Segment	Revenue	Result	Assets	Liabilities	Capital employed	ROCE %
Pharmaceutical	1,396.25	172.27	1,512.64	196.6	1,316.04	13.09
Chemical	1,160.53	30.24